Posted on Oct. 2, 2002, 6:53 a.m. in
A few drops of an enzyme and an inexpensive pair of glasses could one day help to restore sight to the millions of people in developing countries who have lost their sight to cataracts. People suffering from cataracts need surgery to remove them, although in developing countries, where the disease has blinded an estimated 18-million people, surgery is not an option for the vast majority of people. However, Dr. Louis Girard discovered that injecting a few drops of a pancreatic enzyme into the affected eye can chemically displace cataracts. A small pilot study of the treatment restored sight in 80% of those treated. Researchers are now trying to find an agent that does not have to be injected. Girard predicts that the treatment, which is estimated to cost just $3 per person, will become the "simplest and most inexpensive way of curing cataract blindness."
SOURCE/REFERENCE: Reported by www.reutershealth.com on the 1st August 2001
Health Headlines MORE »
Regimen of self-monitoring of blood pressure combined with an individualized self-titration algorithm
Due to its effect on the GI system, antibiotics in early life may raise infectious disease risk in later years.
Compound derivatives of punicalagin may lead to a treatment for Alzheimer’s disease.
Over 1.6 million cardiovascular-related deaths per year can be attributed to sodium consumption above the World Health Organization's recommendation of 2 gm per
Density of street network design, as well as accessible public transportation, can impact residents’ weight and disease risks.
To learn new sequences of movement (motor learning), the brain requires sleep to consolidate the new information.
Use of the Internet and email associates with less cognitive decline, among older men and women.
Dietary supplementation of phosphatidylserine may help to normalize the stress reaction, among men.
Novel optical methods map the pulse pressure of the entire brain's cortex.
A stroke therapy using stem cells extracted from patients' bone marrow has shown promising results in the first trial of its kind in humans.